In this sense, the second strategy using anti-MET and anti-RON mAb-directed drug delivery in the form of an ADC, which has significant increase in the therapeutic index, is likely to be a logical step for MET and RON-targeted cancer therapy. The gene discussed is MET; the disease is cancer.